Why did GAAP earnings fall sharply in 2024 while adjusted earnings grew?

GAAP net earnings were reduced by an $8.3 billion loss on the sale of South American operations and $2.2 billion of cyberattack direct response costs. Management excludes these non-recurring items from adjusted EPS, which rose to $27.66 from $25.12. Adjusted EPS also excludes intangible amortization, which is a recurring cost for an acquisitive company.

Why did the medical care ratio increase, and is it expected to persist?

The full-year medical care ratio rose to 85.5% from 83.2% due to Medicare funding reductions, member mix shifts, the timing of Medicaid redeterminations, increased hospital coding intensity and higher specialty medication prescribing. Management said the coding and specialty drug trends continued at similar levels in Q4 and are reflected in the 2025 outlook.

Is the company's 2025 guidance credible given the 2024 pressures?

UnitedHealth reaffirmed its December 2024 outlook, which includes adjusted EPS of $29.50–30.00 and cash flow from operations of $32–33 billion. The guidance already reflects the 2024 cost trends, but it depends on managing medical costs and on the regulatory and reimbursement environment, including Medicare and Medicaid funding and risk adjustment audits, which are listed as forward-looking risks.

How strong is the company's cash generation and capital return?

Operating cash flow was $24.2 billion in 2024, or 1.6 times net income, and the company returned over $16 billion to shareholders through $7.5 billion in dividends and $9.0 billion in share repurchases. Cash flow was below 2023's $29.1 billion, partly because of working capital changes and cyberattack-related items, and capital spending and acquisitions consumed further cash.

What is the impact of the cyberattack and the South American exit on the business?

The cyberattack reduced Optum Insight revenue by $867 million and produced $2.2 billion of direct response costs, with Optum Insight's operating earnings falling sharply on a GAAP basis. The South American sale produced an $8.3 billion loss on a GAAP basis. Both items are excluded from adjusted results, so investors should monitor whether these costs fully end in 2025.

UNH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 16, 2025. Cited figures are marked; the original filing is the authoritative source.

UnitedHealth Group (UNH) reported fourth-quarter and full-year 2024 results on January 16, 2025 (Item 2.02 of the 8-K, with the press release furnished as Exhibit 99.1).

Full-year revenues rose 8% year-over-year to $400.3 billion^a, driven by Optum Rx, Optum Health and UnitedHealthcare growth, and the company reaffirmed its 2025 outlook of $450–455 billion in revenue, $28.15–28.65 GAAP EPS and $29.50–30.00 adjusted EPS. Reported results were heavily distorted by one-time items: a $8.3 billion loss on the sale of its South American operations and about $2.2 billion of direct cyberattack response costs (plus $867 million of business disruption revenue reductions at Optum Insight). Reported full-year GAAP diluted EPS fell to $15.51 from $23.86, while adjusted EPS rose to $27.66 from $25.12.

Investors should note that the adjusted figures exclude these items and that the full-year medical care ratio rose to 85.5% from 83.2%, reflecting Medicare funding reductions, member mix, Medicaid redeterminations and higher hospital coding intensity and specialty drug prescribing. Those cost pressures are embedded in the 2025 outlook. Cash flow from operations was $24.2 billion^b, or 1.6 times net income, and the company returned over $16 billion to shareholders through dividends and buybacks in 2024.

Balance sheet leverage increased, with long-term debt rising to $72.4 billion^c from $58.3 billion, which partly funded acquisitions and cyberattack-related care provider loans. Fourth-quarter results were in line with the prior year on an adjusted basis, with no favorable prior-year medical reserve development, which makes the margin trajectory into 2025 the key focus for investors.

02—Key points

Key Highlights

Full-year 2024 revenues of $400.3 billion, up 8% year-over-year; Optum revenues grew 12% to $253.0 billion and UnitedHealthcare grew 6% to $298.2 billion.
GAAP diluted EPS fell to $15.51 from $23.86 due to an $8.3 billion loss on the sale of South American operations and $2.2 billion of cyberattack direct response costs; adjusted EPS rose to $27.66 from $25.12.
Full-year medical care ratio rose to 85.5% from 83.2%, driven by Medicare funding reductions, member mix, Medicaid redeterminations and increased hospital coding intensity and specialty drug prescribing.
Operating cost ratio improved to 13.2% from 14.7%, aided by portfolio refinement (about 80 basis points) and operating efficiencies.
Cash flow from operations of $24.2 billion (1.6x net income); over $16 billion returned to shareholders through dividends and share repurchases.
2025 outlook affirmed: revenues of $450–455 billion, GAAP EPS of $28.15–28.65 and adjusted EPS of $29.50–30.00.
Long-term debt increased to $72.4 billion from $58.3 billion year-over-year, and the company recorded no favorable prior-year medical reserve development in Q4.

03—Questions

Frequently Asked Questions

Why did GAAP earnings fall sharply in 2024 while adjusted earnings grew?
GAAP net earnings were reduced by an $8.3 billion loss on the sale of South American operations and $2.2 billion of cyberattack direct response costs. Management excludes these non-recurring items from adjusted EPS, which rose to $27.66 from $25.12. Adjusted EPS also excludes intangible amortization, which is a recurring cost for an acquisitive company.
Why did the medical care ratio increase, and is it expected to persist?
The full-year medical care ratio rose to 85.5% from 83.2% due to Medicare funding reductions, member mix shifts, the timing of Medicaid redeterminations, increased hospital coding intensity and higher specialty medication prescribing. Management said the coding and specialty drug trends continued at similar levels in Q4 and are reflected in the 2025 outlook.
Is the company's 2025 guidance credible given the 2024 pressures?
UnitedHealth reaffirmed its December 2024 outlook, which includes adjusted EPS of $29.50–30.00 and cash flow from operations of $32–33 billion. The guidance already reflects the 2024 cost trends, but it depends on managing medical costs and on the regulatory and reimbursement environment, including Medicare and Medicaid funding and risk adjustment audits, which are listed as forward-looking risks.
How strong is the company's cash generation and capital return?
Operating cash flow was $24.2 billion in 2024, or 1.6 times net income, and the company returned over $16 billion to shareholders through $7.5 billion in dividends and $9.0 billion in share repurchases. Cash flow was below 2023's $29.1 billion, partly because of working capital changes and cyberattack-related items, and capital spending and acquisitions consumed further cash.
What is the impact of the cyberattack and the South American exit on the business?
The cyberattack reduced Optum Insight revenue by $867 million and produced $2.2 billion of direct response costs, with Optum Insight's operating earnings falling sharply on a GAAP basis. The South American sale produced an $8.3 billion loss on a GAAP basis. Both items are excluded from adjusted results, so investors should monitor whether these costs fully end in 2025.

04—Continue

← View all 8-K filings